Cemiplimab in Elderly Patients with Cutaneous Squamous Cell Carcinoma: real-word experience regarding safety and efficacy
Background: Cutaneous squamous cell carcinoma (cSCC) incidence continues to rise with the increasing life expectancy of the aging population. While cemiplimab has shown promising results in the treatment of cSCC, real-world data on its use in the elderly population remain limited. Given that cSCC is more common in older individuals, understanding the treatment efficacy and safety in this group is critical.
Authors
- Carlos‐Filipe Pereira (ORCID: https://orcid.org/0000-0002-9724-1382)
- Emanuel Gouveia (ORCID: https://orcid.org/0000-0001-5768-5539)
- H. Nunes
- J. M. Dias Pereira (ORCID: https://orcid.org/0000-0002-0183-132X)
- Sofia Cabral (ORCID: https://orcid.org/0000-0003-2727-9198)
- Cátia Relvas
- Patrícia M. Pereira (ORCID: https://orcid.org/0000-0002-4828-7632)
- Fátima Vaz (ORCID: https://orcid.org/0000-0002-3722-1080)
- F. Kellen
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100719
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00